Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Hyperparathyroidism Clinical Trials
Hyperparathyroidism clinical trials are recruiting across 13 cities. Here are the cities with the most active studies:
Hyperparathyroidism Trial Phases
6 research organizations are sponsoring hyperparathyroidism trials.
About Hyperparathyroidism
Hyperparathyroidism occurs when the parathyroid glands produce too much parathyroid hormone, leading to elevated blood calcium levels. It can cause kidney stones, bone loss, and other complications. Treatment may include surgery to remove the overactive parathyroid gland.
Clinical trials are advancing new treatments for hyperparathyroidism. Currently, 6 studies are recruiting a combined 522 participants across the United States. Research is being conducted by 6 organizations including National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Florida, The Cleveland Clinic and 3 others.
2026 Hyperparathyroidism Research Landscape
As of October 2026, the hyperparathyroidism clinical trial landscape includes 6 actively recruiting studies across 13 cities in the United States. These studies are collectively seeking 522 participants, with an average enrollment target of 87 per study.
The research spans multiple phases of development: 2 studies are in PHASE3, 2 studies are in NA, 1 study is in PHASE2, 1 study is in PHASE4. The presence of Phase 3 trials indicates that some hyperparathyroidism treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 6 different organizations, including National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Florida, The Cleveland Clinic, University of Pennsylvania, Amgen, and 1 others.
Geographically, hyperparathyroidism trials are most concentrated in Cleveland, Ohio (2 trials); Philadelphia, Pennsylvania (2 trials); Bethesda, Maryland (1 trial); Gainesville, Florida (1 trial); Los Angeles, California (1 trial) and 7 other cities.
Featured Hyperparathyroidism Studies
Highlighted recruiting studies for hyperparathyroidism, selected by enrollment size and research scope.
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
Background: People have 4 parathyroid glands near the thyroid gland in the neck. Surgery is needed to remove a parathyroid gland that is too large or has a tumor. These glands can be in different places, so doctors use an imaging scan with contrast dye to help find them before surgery. Researchers want to know if a different type of scan and a new tracer can make it easier to find the tumors in t...
Parathyroidectomy and Mobility Study
This study evaluates whether surgical removal of the parathyroid gland (parathyroidectomy) improves physical function and mobility in older adults with primary hyperparathyroidism (PHPT). PHPT, a common endocrine disorder in older adults, is associated with reduced muscle strength, mobility, and quality of life. This prospective observational study will enroll up to 80 participants aged 60 and old...
NIRAF-camera Versus Conventional Surgery in Preoperative Imaging Negative Primary Hyperparathyroidism
Primary hyperparathyroidism (PHPT) is a prevalent endocrine disorder, with an estimated prevalence of 0.86% in the United States. The only definitive treatment for PHPT is parathyroidectomy. Preoperative localization of abnormal parathyroid glands (PGs) is typically achieved using ultrasound imaging and 99mTc-sestamibi scans, which aid in surgical planning and reducing intraoperative gland detecti...
Frequently Asked Questions About Hyperparathyroidism Clinical Trials
Are there hyperparathyroidism clinical trials near me?
Yes, there are 6 hyperparathyroidism clinical trials currently recruiting across 13+ cities in the United States, including Cleveland, Ohio; Philadelphia, Pennsylvania; Bethesda, Maryland. Browse the studies above to find one at a location convenient for you.
How do I join a hyperparathyroidism clinical trial?
To join a hyperparathyroidism clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are hyperparathyroidism clinical trials free?
Yes, participation in hyperparathyroidism clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of hyperparathyroidism treatments are being studied?
Current hyperparathyroidism clinical trials are testing a range of approaches across PHASE3 (2 studies), NA (2 studies), PHASE2 (1 study), PHASE4 (1 study). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 6 research organizations.
Is it safe to participate in hyperparathyroidism clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated October 14, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated October 14, 2026 · Data from ClinicalTrials.gov